What To Look Out For At ESC 2024

Full data on heart disease products from Alnylam, Bayer and others will take center stage at the cardiology meeting later this month.    

Autumn red leaf with cut heart in a hand - Image

The past year has seen several high-profile Phase III cardiology successes toplined by various biopharma firms – and at least one disaster. The annual congress of the European Society of Cardiology (ESC), which takes place in London, UK, from 30 August-2 September, will provide a chance to engage with the data in more depth.

Key Takeaways
  • The annual meeting of the European Society of Cardiology is approaching and will see several intriguing and commercially significant presentations.
  • Three Hot Line sessions, covering Alnylam’s Amvuttra...

One of the coveted Hot Line slots, in the very first of these sessions, has been taken by the HELIOS-B trial of Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran) in patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

More from R&D

Public Health And Innovation: Addressing Gaps, Pharma’s Role

 

Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

ASCO: AstraZeneca Changes Management Of Breast Cancer Resistance With SERENA-6

 

AstraZeneca presented data from the SERENA-6 trial that experts said could represent a significant change in how HR+/HER2- breast cancer is treated.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.